Alnylam Pharmaceuticals Cash on Hand 2010-2025 | ALNY

Alnylam Pharmaceuticals cash on hand for the quarter ending March 31, 2025 was $2.632B, a 11% increase year-over-year.

  • Alnylam Pharmaceuticals cash on hand for 2024 was $2.695B, a 10.46% increase from 2023.
  • Alnylam Pharmaceuticals cash on hand for 2023 was $2.439B, a 11.27% increase from 2022.
  • Alnylam Pharmaceuticals cash on hand for 2022 was $2.192B, a 9.98% decline from 2021.

Alnylam Pharmaceuticals Cash on Hand 2010-2025 | ALNY

  • Alnylam Pharmaceuticals cash on hand for 2024 was $2.695B, a 10.46% increase from 2023.
  • Alnylam Pharmaceuticals cash on hand for 2023 was $2.439B, a 11.27% increase from 2022.
  • Alnylam Pharmaceuticals cash on hand for 2022 was $2.192B, a 9.98% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$229.4B
Amgen (AMGN)$163.2B
Gilead Sciences (GILD)$142.1B
Vertex Pharmaceuticals (VRTX)$120.3B
Bristol Myers Squibb (BMY)$95.4B
CSL (CSLLY)$86B
GSK (GSK)$76.9B
Regeneron Pharmaceuticals (REGN)$60.3B
Argenex SE (ARGX)$36.6B
BioNTech SE (BNTX)$26.8B
Royalty Pharma (RPRX)$21B
Insmed (INSM)$19.9B
Biogen (BIIB)$18.7B
Illumina (ILMN)$17.2B
Incyte (INCY)$15B
Genmab (GNMSF)$14.7B
Genmab (GMAB)$14.5B
Moderna (MRNA)$12.6B
QIAGEN (QGEN)$11.4B
BioMarin Pharmaceutical (BMRN)$11.2B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10B
Exelixis (EXEL)$9.9B
Bio-Techne Corp (TECH)$9.1B
Exact Sciences (EXAS)$9B
Verona Pharma American Depositary Share (VRNA)$9B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$7.8B
Legend Biotech (LEGN)$7.5B
Halozyme Therapeutics (HALO)$7.3B